Argentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF-endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82% -99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60% -94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.
Arenaviruses are important causes of hemorrhagic fever synArgentine hemorrhagic fever (AHF) is an acute arenavirus infection caused by Junin virus. AHF has been a major public dromes across the globe [1] . Lassa, Machupo (Bolivian hemorrhagic fever), Guanarito (Venezuelan hemorrhagic fever), and health problem in a well-defined AHF-endemic area of northcentral Argentina, with 100 -800 cases diagnosed each year Sabia viruses have caused outbreaks of severe natural or laboratory-acquired disease. Lymphocytic choriomeningitis virus, [2, 3] . Most infections occur in 15-to 60-year-old male agricultural workers during an epidemic season that peaks in coincithe prototype of the family, is an important cause of benign nonspecific febrile illness and aseptic meningitis worldwide dence with the annual grain harvests (March -June); disease is recognized year-round among both male and female workers but may cause lethal infections as well.
of all age groups, however. Patients with severe AHF develop extensive hemorrhagic manifestations, shock, and seizures. The case-fatality ratio among untreated patients has been 15% - Received 16 June 1997; revised 8 September 1997.
30%. Treatment with plasma from patients who have recovered
Written informed consent was obtained from all patients or their parents. Human experimentation guidelines of the authors' institutions were followed from AHF reduces the mortality of acute disease to £1%, in the conduct of this clinical research. The study protocol was approved by but a late neurologic syndrome of unknown etiology has been the Comité de Evaluación É tica de Investigaciones Biomédicas de INEVH, observed in 10% of survivors [4] . The rodent Calomys musculi- [5, 6] . A passive ologic studies that demonstrated a high AHF incidence relative to case detection system for possible adverse events associated with that of surrounding localities. The study area was located near the inoculation and episodes of AHF was in place throughout the coordinating institution, the Instituto Nacional de Estudios sobre study. Volunteers were given a card with a brief description of Virosis Hemorrágicas (INEVH), in Pergamino, Buenos Aires the study, telephone numbers of the investigators, and signs and Province, where patients with AHF have been treated for ú20 symptoms of AHF. Local physicians had a list of study volunteers years. The annual incidence of AHF cases among males in the and were instructed to refer volunteers with adverse events or study area was 2.2/1000. The at-risk population from which resuspected AHF to INEVH for evaluation. At INEVH, volunteers cruitment took place was estimated to be 21,000.
were evaluated and admitted to the hospital for observation or, if Enrollment of volunteers. Between May and July 1988, an the illness was not felt to be AHF, treated as outpatients. Adverse extensive public relations campaign incorporating video, audio, events occurring within 2 weeks of inoculation and deaths were and print media was conducted throughout the vaccine target rerecorded and analyzed independently as to whether there was likely gion. In each of the 41 selected localities, meetings were held with causality between the event and participation in the study. local governmental authorities, medical and paramedical personVolunteers hospitalized for suspected AHF were evaluated daily nel, and the population at large. Formal vaccine committees were for clinical status: WBC and platelet counts and blood urea nitroestablished in each locality to facilitate the recruitment, enrollment, gen and serum aspartate aminotransferase levels were monitored and follow-up of volunteers.
daily. Blood for Junin virus serology was collected every third Individuals were considered to be eligible if they were healthy, day. Blood for virus isolation was obtained during the first 3 days male, 15-64 years old, resided or worked in a rural agricultural of hospitalization. Patients with petechiae or thrombocytopenia area of the 41-county area, had no history of AHF, had normal and other signs suggestive of AHF were treated with immune baseline blood values (white blood cell [WBC] and differential plasma. The clinicians caring for the patients recorded their final counts, platelet count, hematocrit, serum glucose level, serum crediagnoses without knowing the results of the virologic studies or atinine level, and serum aspartate aminotransferase levels), were the final clinical case definition of AHF to be used for the calculanegative on screening for human immunodeficiency virus infection of vaccine efficacy. tion, and had no known allergies to vaccine components. VolunCase definitions for AHF. Clinical and laboratory case definiteers with chronic disease states associated with altered immunity tions were based on a retrospective case-control study of previous (e.g., malignancy, autoimmune disorders, asplenia) were not allaboratory-confirmed AHF cases and were developed before the lowed to participate. Females were excluded because of the uncode was broken [11] . A definite clinical case was a volunteer known effect of Candid 1 on pregnancy and their lower (by at with suspected AHF who had a WBC count of õ2500/mm 3 and least 4-fold) risk of AHF. Potential participants were screened by a platelet count of õ100,000/mm 3 . This definition had a sensitivity use of a clinical history and physical examination, and a blood of 87% and a specificity of 88% for patients with laboratorysample was taken for Junin virus antibody measurement. Records confirmed AHF (4-fold rise in Junin virus neutralizing antibody were independently reviewed at INEVH to establish final volunteer between acute and convalescent specimens) in the retrospective eligibility. Eligible volunteers were randomized to receive either study. Participants with illnesses not meeting the definite case placebo or vaccine in blocks of 6 persons (3 vaccine, 3 placebo) definition who had platelet counts of õ120,000/mm 3 and one or within each of the 41 counties to insure a similar distribution of more of axillary petechiae, gingival bleeding, the late neurologic vaccine and placebo recipients by county because of the highly syndrome, or a WBC count of õ2500 /mm 3 were classified as focal nature of the disease. The randomization code was stored at having a possible clinical case. This definition had a sensitivity the US Army Medical Research Institute of Infectious Diseases and specificity of 90% and 71%, respectively, in the retrospective (USAMRIID) and was not available to either the Argentine or the study. US study investigators.
Volunteers with either a 4-fold rise in antibody titer or the Inoculations began on 3 October 1988 and were halted in Januisolation of Junin virus from plasma were classified as having ary 1989 due to the impending onset of the AHF epidemic season, laboratory-confirmed Junin virus infection. The classification of which usually begins in late February or early March. Additional volunteers according to the clinical definitions outlined above was participants were recruited during a second round of immunization done by computer analyses of coded clinical data and was made that occurred 11 November to 16 December 1989. A single 1-mL independently of the results of the serologic or virologic studies. dose of either vaccine diluent or 40,000 pfu of Candid 1 was Case definitions were developed independently before the individinjected into the deltoid muscle. Volunteers were instructed to go ual clinical and laboratory data from volunteers were examined. to a local designated clinic to see their primary care physicians if Two primary end points were evaluated: definite or possible they developed fever, malaise, or other troublesome symptoms at clinical case of AHF with laboratory-documented Junin virus inany time during the study.
fection and laboratory-documented infection with Junin virus, inFollowing inoculation, volunteers were evaluated before and dependent of clinical findings. Volunteers presenting with a clinical after each AHF epidemic season. Volunteers enrolled during the complaint by 31 July 1990 were included in the efficacy analyses. first round of inoculations were followed for two seasons, and
The clinical and laboratory data from every symptomatic volunteer those inoculated during the second round were followed for one evaluated for possible infection with Junin virus were reviewed, season. At each visit, any history of illness possibly consistent and each volunteer was classified according to the above case definitions. with AHF or hospital admission (or both) was recorded, and a / 9d3f$$fe34
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Vaccine preparation. Details of the preparation and testing Junin virus antibody measurements. Serum neutralizing antibodies were measured using a complement-enhanced plaque-reof Candid 1 vaccine are contained in the US Food and Drug duction neutralization test, as previously described [17] . A seroAdministration's Investigational New Drug Application #2257. In logic response to inoculation was defined as a §4-fold rise in brief, Candid #1 was derived from a documented descendent of neutralizing antibody titer between pre-and postinoculation sera. the prototype XJ strain Junin virus, originally isolated from a fatal A serologic response to an illness was defined as a §4-fold rise case of AHF. Following 44 newborn mouse brain passages beyond in neutralizing antibody titer between acute and convalescent sera the initial guinea pig isolation and passage (GPp2MBp44), the run in the same test and confirmed by repeat testing. Serologic candidate vaccine strain was cloned by single-burst selection and testing was conducted after the vaccine trial was completed by passed in certified fetal rhesus lung cells (FRLp19; Barrera Oro laboratory personnel who were unaware of vaccine or placebo J, Eddy G, unpublished data) [7, 8, 12] . The vaccine was then assignment. extensively tested to ensure freedom from contamination by advenVirus isolation. Junin virus isolation was attempted from both titious agents. Candid 1 was found to be significantly more attenu-PBMC and plasma from subjects with suspected AHF. PBMC ated in newborn mice and guinea pigs than an earlier generation were cocultivated with VERO cell monolayers in duplicate to facilJunin virus vaccine (XJ clone 3) [8] and appeared to be less able itate virus recovery [18] . Infected cells from the monolayer were to replicate in macaques than wild-type Junin virus [9, 10] .
identified by immunofluorescence using a fluorescein isothiocyaIn initial human trials, Candid 1 was found to be safe and nate-conjugated rabbit anti-Junin virus antiserum. Culture superhighly immunogenic [13, 14] . Among 83 volunteers inoculated at natant fluids were assayed directly by plaquing on VERO cells. USAMRIID in cohorts of various size using a variety of dosage All samples were passaged blindly through four cycles (unless and inoculation routes, the vaccine was found to be well tolerated interrupted by contamination) before being considered negative clinically during follow-up periods ranging from 1 month to 2 for the presence of virus. The same methods were used for the years. Fourteen Argentine volunteers were inoculated concurrently isolation of Junin virus from plasma. at INEVH, with similar findings. Laboratory parameters were exStatistical analysis. Vaccine efficacy (percentage) was calcutensively assessed, including routine hematologic measurements; lated using the formula [(attack rate in the placebo group)0(attack urinalyses; coagulation studies; measurements of muscle enzymes; rate in the vaccine group)]/(attack rate in the placebo group) 1 amylase, hepatic, and renal function assays; serum levels of immu-100%. Attack rates were calculated per 10,000 person-seasons of noglobulins, complement, and interferon; and T lymphocytes and exposure. The 2-tailed exact binomial test was used to compare subsets; no significant abnormalities were detected. Virus isolation the attack rates per person-season exposure [19] . Fisher's exact or attempts from throat, plasma, peripheral blood mononuclear cells x 2 tests were used to compare rates, and t tests were used for (PBMC), urine, and semen in 46 vaccinees yielded positive results continuous measurements. from PBMC only, in 7 subjects during a window 7-13 days after vaccination; virus could be recovered on only 1 day from 6 of 7 subjects, while the maximum duration of viremia was 3 days. (table 1) . Of these, 5927 were enrolled during the first round cal, or urinary abnormalities [15] . Fifteen persons (27%) developed of inoculations, and 573 were enrolled during the second round. to 64,000 pfu/mL (mean Å 48,000 pfu/mL), demonstrating stabil-NOTE. None of the differences was statistically significant.
Results

Among
ity and site-to-site consistency.
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There was no difference in the distribution of vaccine and significantly more often in vaccinees than in placebo recipients was headache with constitutional symptoms. The numbers of placebo recipients by county (P Å 1.00).
Preinoculation sera from 88 (2.7%) of the vaccine group and deaths were similar in both study groups (table 3) . One death occurred during the first 30 days after inoculation in a 36-year-81 (2.5%) of the placebo group were found to have Junin virus antibody titers of §1:4, (P Å .60). Among these seropositive old man who had received Candid 1 vaccine. This patient developed gas gangrene of the buttock several days after an volunteers, 52 (59.1%) vaccine recipients versus 60 (74.1%) placebo recipients had a baseline antibody titer of §1:256 intramuscular corticosteroid injection at that site for low back pain using a reusable needle and syringe. He had received (P Å .05). No AHF cases were subsequently observed among these seropositive persons. Baseline Junin virus antibody titers Candid 1 in the left deltoid muscle 1 week previously. None of the deaths during the study was judged to be related to were not available for 178 volunteers, 88 (2.8%) in the vaccine group and 90 (2.9%) in the placebo group (P Å .86); these immunization.
Vaccine efficacy. A total of 255 volunteers presented to persons were included in all analyses.
Vaccine immunogenicity and reactogenicity. Among the their primary physicians with complaints. Of these, 94 were referred to INEVH for evaluation of possible AHF, 65 of whom seronegative volunteers, at least 1 serum sample was available within 6 months of inoculation for 2818 vaccine and 2842 were hospitalized. Laboratory evidence for Junin virus infection was obtained for 29 ill patients; 23 of these met the clinical placebo recipients. The mean interval between inoculation and the first neutralizing antibody titer measurement was 5 months case definition for AHF. Analysis of the entire study cohort (intent-to-treat analysis) revealed that among the 23 men with for both groups. Among vaccine recipients, 91.1% had seroconverted (range, õ1:4 to §1:4096); 0.7% of placebo recipients AHF, 22 had received placebo (35.5 cases/10,000 person-seasons of follow-up) and 1 had received vaccine (1.6 cases/10,000 developed antibody during this 5-month period. The geometric mean neutralizing antibody titer among vaccine recipients was person-seasons); vaccine efficacy for protection against AHF was 95% (95% CI, 82% -99%; P õ .001). Among the 29 men 1:152 versus õ1:4 for placebo recipients (P Å .0001). Among the placebo recipients, 18 (0.6%) had a postinoculation antiwho presented with clinical complaints who were found to have evidence of Junin virus infection, 25 had received placebo body titer of §1:256 compared with 1542 (55%) of Candid 1 recipients (P õ.001). For all volunteers who met the AHF case (40.3 cases/10,000 person-seasons) and 4 had received vaccine (6.4 cases/10,000 person-seasons), for an efficacy of 84% (95% definition, the initial postinoculation antibody determinations were done before the onset of AHF.
CI, 60% -94%; P õ .001) against infection associated with any clinical symptoms. The 25 cases in the placebo group Adverse events. Within the first 2 weeks after inoculation, 36 (1.1%) of the vaccine recipients had one or more reported meeting the laboratory case definition occurred among residents of 18 counties; the 4 cases in the vaccinated group (''vacadverse events, versus 14 (0.4%) of the placebo recipients (P Å .002; table 2). The only single adverse event that occurred cine failures'') occurred in 4 counties. A secondary analysis, excluding the 169 volunteers found to be seropositive at study entry, yielded identical estimates of vaccine efficacy (data not shown). with unknown baseline serologic status. Excluding these volunteers did not alter the estimates of vaccine efficacy. The likelihood that these volunteers were seropositive at baseline was at the end of the study according to the case definitions could low, and they were equally distributed between the vaccine not be fully blinded to the vaccination status of the volunteers and placebo groups.
because vaccine recipients were more likely to have had meaThe efficacy of Candid 1 for protection against any Junin surable neutralizing antibodies at the time of evaluation for virus infections may have been lower had we been able to test suspected AHF. However, the volunteers were evaluated for all volunteers for seroconversion at the end of the follow-up the clinical component of the case definition before the results period. We believe that an analysis of subjects who presented of the virologic studies were known, and the case definitions with illness provides the most clinically meaningful measure were based on predetermined objective criteria that could not of protection. The investigators who classified the volunteers be easily compromised by investigator bias. All patients hospitalized at INEVH for whom a diagnosis of AHF is suspected on clinical grounds receive immune plasma 
